| [1] Ghoneim MA, AbdelLatif M, Mekresh M, et al.Radical cystectomy for carcinoma of the bladder:2, 720 consecutive cases 5 years later[J].J Urol, 2008, 180(1):121-127.[2] Stünkel W, Peh BK, Tan YC, et al. Function of the SIRT1 protein deacetylase in cancer[J]. Biotechnol J, 2007, (2): 1360-1368.[3] Jang KY, Noh SJ, Lehwald N, et al. SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas[J]. PLoS ONE, 2012, 7(9): e45119.[4] Knight JR, Milner J. SIRT1, metabolism and cancer[J]. Curr Opin Oncol, 2012, 24(1):68-75.[5] Chen WY, Wang DH, Yen RC, et al. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses[J]. Cell, 2005, 123(3):437-448.[6] Chen HC, Jeng YM, Yuan RH, et al. SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis[J]. Ann Surg Oncol, 2012, 19(6):2011-2019.[7] Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis[J]. Proc Natl Acad Sci USA, 2008, 105(36):13421-13426.[8] Brunet A, Sweeney LB, Sturgill JF, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase[J]. Science, 2004, 303(5666):2011-2015.[9] Lee JH, Song MY, Song EK, et al. Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway[J]. 2009, 58(2):344-351.[10] Sang JN, Myoung JK, Kyoung MK, et al. Acetylation status of p53 and the expression of DBC1, SIRT1 and androgen receptor are associated with survival in clear cell renal cell carcinoma patients[J]. Pathology, 2013, 45(6):574-580. |
